Verastem Oncology to Participate in Upcoming Investor Conferences
Verastem Oncology (Nasdaq: VSTM) has announced its management team's upcoming participation in two major investor conferences. The company will attend the 2024 Truist Securities BioPharma Symposium on November 7 and participate in a fireside chat at the 2024 Guggenheim Healthcare Innovation Conference on November 13 at 9:00 am EDT.
The fireside chat will be accessible via live webcast in the Events & Presentations section of Verastem's website, with a replay available for approximately 90 days post-presentation.
Verastem Oncology (Nasdaq: VSTM) ha annunciato la prossima partecipazione del suo team di gestione a due importanti conferenze per investitori. L'azienda parteciperà al 2024 Truist Securities BioPharma Symposium il 7 novembre e prenderà parte a una conversazione informale al 2024 Guggenheim Healthcare Innovation Conference il 13 novembre alle 9:00 EDT.
La conversazione informale sarà accessibile tramite webcast dal vivo nella sezione Eventi e Presentazioni del sito web di Verastem, con una registrazione disponibile per circa 90 giorni dopo la presentazione.
Verastem Oncology (Nasdaq: VSTM) ha anunciado la próxima participación de su equipo de gestión en dos importantes conferencias para inversores. La compañía asistirá al 2024 Truist Securities BioPharma Symposium el 7 de noviembre y participará en una charla informal en la 2024 Guggenheim Healthcare Innovation Conference el 13 de noviembre a las 9:00 am EDT.
La charla informal será accesible a través de una transmisión en vivo en la sección de Eventos y Presentaciones del sitio web de Verastem, con una repetición disponible durante aproximadamente 90 días después de la presentación.
Verastem Oncology (Nasdaq: VSTM)는 경영진팀이 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다. 회사는 11월 7일에 열리는 2024 Truist Securities BioPharma Symposium에 참석하고, 11월 13일 EDT 오전 9시에 2024 Guggenheim Healthcare Innovation Conference에서 화기애애한 대담에 참여할 예정입니다.
화기애애한 대담은 Verastem의 웹사이트 이벤트 및 발표 섹션에서 라이브 웹캐스트를 통해 시청할 수 있으며, 발표 후 약 90일 동안 다시 볼 수 있습니다.
Verastem Oncology (Nasdaq: VSTM) a annoncé la participation prochaine de son équipe de direction à deux grandes conférences pour investisseurs. La société assistera au 2024 Truist Securities BioPharma Symposium le 7 novembre et participera à un entretien informel lors de la 2024 Guggenheim Healthcare Innovation Conference le 13 novembre à 9h00 EDT.
L'entretien informel sera accessible via un webinaire en direct dans la section Événements & Présentations du site web de Verastem, avec une rediffusion disponible pendant environ 90 jours après la présentation.
Verastem Oncology (Nasdaq: VSTM) hat die bevorstehende Teilnahme seines Management-Teams an zwei bedeutenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 7. November am 2024 Truist Securities BioPharma Symposium teilnehmen und am 13. November um 9:00 Uhr EDT an einem informellen Gespräch auf der 2024 Guggenheim Healthcare Innovation Conference mitwirken.
Das informelle Gespräch wird über einen Live-Webcast im Bereich Veranstaltungen & Präsentationen der Website von Verastem zugänglich sein, wobei eine Wiederholung für etwa 90 Tage nach der Präsentation verfügbar sein wird.
- None.
- None.
- 2024 Truist Securities BioPharma Symposium on November 7, 2024
- Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT
A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030694764/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
When is Verastem Oncology (VSTM) presenting at the Guggenheim Healthcare Innovation Conference 2024?
Which investor conferences is Verastem Oncology (VSTM) attending in November 2024?
How long will the webcast replay be available for Verastem's (VSTM) Guggenheim Conference presentation?
Where can I watch Verastem Oncology's (VSTM) investor conference presentations?
